Parthenolide induces superoxide anion production by stimulating EGF receptor in MDA-MB-231 breast cancer cells

D'Anneo,A.; Carlisi,D.; Emanuele,S.; Buttitta,G.; Di Fiore,R.; Vento,R.; Tesoriere,G.; Lauricella,M.

doi:10.3892/ijo.2013.2137

Parthenolide induces superoxide anion production by stimulating EGF receptor in MDA-MB-231 breast cancer cells

Authors:
- A. D'Anneo
- D. Carlisi
- S. Emanuele
- G. Buttitta
- R. Di Fiore
- R. Vento
- G. Tesoriere
- M. Lauricella
View Affiliations

Affiliations: Laboratory of Biochemistry, Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy, Laboratory of Biochemistry, Department of Experimental Biomedicine and Clinical Neurosciences, Polyclinic, University of Palermo, Palermo, Italy
Published online on: October 14, 2013 https://doi.org/10.3892/ijo.2013.2137
Pages: 1895-1900

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The sesquiterpene lactone parthenolide (PN) has recently attracted considerable attention because of its anti-microbial, anti-inflammatory and anticancer effects. However, the mechanism of its cytotoxic action on tumor cells remains scarcely defined. We recently provided evidence that the effect exerted by PN in MDA-MB-231 breast cancer cells was mediated by the production of reactive oxygen species (ROS). The present study shows that PN promoted the phosphorylation of EGF receptor (phospho-EGFR) at Tyr1173, an event which was observed already at 1 h of incubation with 25 µM PN and reached a peak at 8-16 h. This effect seemed to be a consequence of ROS production, because N-acetylcysteine (NAC), a powerful ROS scavenger, prevented the increment of phospho-EGFR levels. In addition fluorescence analyses performed using dihydroethidium demonstrated that PN stimulated the production of superoxide anion already at 2-3 h of incubation and the effect further increased prolonging the time of treatment, reaching a peak at 8-16 h. Superoxide anion production was markedly hampered by apocynin, a well known NADPH oxidase (NOX) inhibitor, suggesting that the effect was dependent on NOX activity. The finding that AG1478, an EGFR kinase inhibitor, substantially blocked both EGFR phosphorylation and superoxide anion production strongly suggested that phosphorylation of EGFR can be responsible for the activation of NOX with the consequent production of superoxide anion. Therefore, EGFR phosphorylation can exert a key role in the production of superoxide anion and ROS induced by PN in MDA-MB-231 cells.

View Figures

View References

1.	Ghantous A, Sinjab A, Herceg Z and Darwiche N: Parthenolide: from plant shoots to cancer roots. Drug Discov Today. 18:894–905. 2013. View Article : Google Scholar : PubMed/NCBI
2.	Kim SL, Trang KT, Kim SH, Kim IH, Lee SO, Lee ST, Kim DG and Kim SW: Parthenolide suppresses tumor growth in a xenograft model of colorectal cancer cells by inducing mitochondrial dysfunction and apoptosis. Int J Oncol. 41:1547–1553. 2012.PubMed/NCBI
3.	Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA and Schmidt CM: Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther. 4:587–594. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Sun Y, St Clair DK, Xu Y, Crooks PA and St Clair WH: A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res. 70:2880–2890. 2010. View Article : Google Scholar
5.	Wang W, Adachi M, Kawamura R, Sakamoto H, Hayashi T, Ishida T, Imai K and Shinomura Y: Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis. 11:2225–2235. 2006. View Article : Google Scholar
6.	D’Anneo A, Carlisi D, Lauricella M, Emanuele S, Di Fiore R, Vento R and Tesoriere G: Parthenolide induces caspase-independent and AIF-mediated cell death in human osteosarcoma and melanoma cells. J Cell Physiol. 228:952–967. 2013.PubMed/NCBI
7.	D’Anneo A, Carlisi D, Lauricella M, Puleio R, Martinez R, Di Bella S, Di Marco P, Emanuele S, Di Fiore R, Guercio A, Vento R and Tesoriere G: Parthenolide generates reactive oxygen species and autophagy in MDA-MB-231 cells A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis. (In press).
8.	Bazley LA and Gullick WJ: The epidermal growth factor receptor family. Endocr Relat Cancer. 12:17–27. 2005. View Article : Google Scholar
9.	Hölsken A, Gebhardt M, Buchfelder M, Fahlbusch R, Blümcke I and Buslei R: EGFR signaling regulates tumor cell migration in craniopharyngiomas. Clin Cancer Res. 17:4367–4377. 2011.PubMed/NCBI
10.	Zhang J, Li H, Wang J, Dong Z, Mian S and Yu FS: Role of EGFR transactivation in preventing apoptosis in Pseudomonas aeruginosa-infected human corneal epithelial cells. Invest Ophthalmol Vis Sci. 45:2569–2576. 2004. View Article : Google Scholar : PubMed/NCBI
11.	van Cruijsen H, Giaccone G and Hoekman K: Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer. 118:883–888. 2006.PubMed/NCBI
12.	Macias A, Azavedo E, Hagerstrom T, Klintenberg C, Perez R and Skoog L: Prognostic significance of the receptor for epidermal growth factor in human mammary carcinomas. Anticancer Res. 7:459–464. 1987.PubMed/NCBI
13.	Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE and Lynch TJ: Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 12:90–98. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Bae YS, Kang SW, Seo MS, Baines IC, Tekle E, Chock PB and Rhee SG: Epidermal growth factor (EGF)-induced generation of hydrogen peroxide. Role in EGF receptor-mediated tyrosine phosphorylation. J Biol Chem. 272:217–221. 1997. View Article : Google Scholar : PubMed/NCBI
15.	Cuddihy SL, Winterbourn CC and Hampton MB: Assessment of redox changes to hydrogen peroxide-sensitive proteins during EGF signaling. Antioxid Redox Signal. 15:167–174. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Truong TH and Carroll KS: Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation. Biochemistry. 51:9954–9965. 2012. View Article : Google Scholar : PubMed/NCBI
17.	Chiarugi P, Pani G, Giannoni E, Taddei L, Colavitti R, Raugei G, Symons M, Borrello S, Galeotti T and Ramponi G: Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J Cell Biol. 161:933–944. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Jagadeesha DK, Takapoo M, Banfi B, Bhalla RC and Miller FJ Jr: Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc Res. 93:406–413. 2012. View Article : Google Scholar : PubMed/NCBI
19.	Giuliano M, Lauricella M, Calvaruso G, Carabillò M, Emanuele S, Vento R and Tesoriere G: The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res. 59:5586–5595. 1999.PubMed/NCBI
20.	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
21.	Voldborg BR, Damstrup L, Spang-Thomsen M and Poulsen HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 8:1197–1206. 1997. View Article : Google Scholar : PubMed/NCBI
22.	Paletta-Silva R, Rocco-Machado N and Meyer-Fernandes JR: NADPH oxidase biology and the regulation of tyrosine kinase receptor signaling and cancer drug cytotoxicity. Int J Mol Sci. 14:3683–3704. 2013. View Article : Google Scholar : PubMed/NCBI
23.	Hordijk PL: Regulation of NADPH oxidases: the role of Rac proteins. Circ Res. 98:453–462. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Boudreau HE, Casterline BW, Rada B, Korzeniowska A and Leto TL: Nox4 involvement in TGF-beta and SMAD3-driven induction of the epithelial-to-mesenchymal transition and migration of breast epithelial cells. Free Radic Biol Med. 53:1489–1499. 2012. View Article : Google Scholar : PubMed/NCBI
25.	Wu F, Tyml K and Wilson JX: iNOS expression requires NADPH oxidase-dependent redox signaling in microvascular endothelial cells. J Cell Physiol. 117:207–214. 2008. View Article : Google Scholar : PubMed/NCBI
26.	Zhua XF, Liua ZC, Xiea BF, Lia ZM, Fenga GK, Yangb D and Zeng YX: EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 169:27–32. 2001. View Article : Google Scholar : PubMed/NCBI
27.	Schlessinger J: Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 110:669–672. 2002. View Article : Google Scholar : PubMed/NCBI
28.	Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T and Mitsudomi T: Mutations of epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar
29.	Rampaul RS, Pinder SE, Nicholson RI, Gullick WJ, Robertson JF and Ellis IO: Clinical value of epidermal growth factor receptor expression in primary breast cancer. Adv Anat Pathol. 12:271–273. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Lauricella M, Ciraolo A, Carlisi D, Vento R and Tesoriere G: SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells. Biochimie. 94:287–299. 2012. View Article : Google Scholar
31.	Lee CS, Hall RE, Alexander IE, Koga M, Shine J and Sutherland RL: Inverse relationship between estrogen receptor and epidermal growth factor. Growth Factors. 3:97–103. 1990. View Article : Google Scholar : PubMed/NCBI
32.	Gamou S and Shimizu N: Hydrogen peroxide preferentially enhances the tyrosine phosphorylation of epidermal growth factor receptor. FEBS Lett. 357:161–164. 1995. View Article : Google Scholar : PubMed/NCBI
33.	Haj FG, Markova B, Klaman LD, Bohmer FD and Neel BG: Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem. 278:739–744. 2003. View Article : Google Scholar : PubMed/NCBI
34.	Chiarugi P: PTPs versus PTKs: the redox side of the coin. Free Radic Res. 39:353–364. 2005. View Article : Google Scholar : PubMed/NCBI
35.	Paulsen CE, Truong TH, Garcia FJ, Homann A, Gupta V, Leonard SE and Carroll KS: Peroxide-dependent sulfenylation of the EGFR catalytic site enhances kinase activity. Nat Chem Biol. 8:57–64. 2011. View Article : Google Scholar : PubMed/NCBI
36.	Tamas P, Solti Z, Bauer P, Illes A, Sipeki S, Bauer A, Farago A, Downward J and Buday L: Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac. J Biol Chem. 278:5163–5171. 2003. View Article : Google Scholar : PubMed/NCBI
37.	Sheng ZG, Huang W, Liu YX, Yuan Y and Zhu BZ: Ofloxacin induces apoptosis via β1 integrin-EGFR-Rac1-Nox2 pathway in microencapsulated chondrocytes. Toxicol Appl Pharmacol. 267:74–87. 2013.PubMed/NCBI